La Universal Research Center — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$30,078	1
2024	Research	$203,935	2
2023	Research	$150,628	1
2022	Research	$27,480	2
2021	Research	$142,297	2
2020	Research	$469,792	2
2019	Research	$191,214	4

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $1,207,509 11 payments
LEO Pharma AS $7,915 3 payments

Studies the money was for Research payments · program years 2019–2025

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod $383,773 1 payment
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis $314,463 4 payments
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis $183,299 1 payment
Phase III Long Term Roll Over Psoriasis $150,628 1 payment
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis $145,168 2 payments
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to $27,696 1 payment
Tralokinumab Vaccine Response Time $7,915 3 payments
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis $2,481 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.